NCT05330169

Hearing Impairment of Nasopharyngeal Carcinoma

Prospective Observational Cohort Study to Evaluate Hearing Toxicity Before and After Chemoradiotherapy in Patients With Nasopharyngeal Carcinoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Guangxi Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This observational cohort study was aimed to evaluate the hearing toxicity at multiple time points from baseline to 1 year after radical chemoradiotherapy among nasopharyngeal carcinoma patients.

Detailed description

With the development of radiotherapeutic techniques and equipment as well as advances in treatment modalities, the 5-year overall survival of patients with non-disseminated NPC has exceeded 80%. However, the incidence of hearing toxicity did not decrease significantly compared with the past. The hearing loss remains the second most common toxicity after xerostomia. Audiometry, acoustic impedance testing, eustachian tube pressure measurements, and distortion product otoacoustic emissions will be used to compare hearing before treatment and up to 1 year after radical chemoradiotherapy. The related factors affecting the hearing of NPC patients will also be investigated and explored.

Conditions

• Nasopharyngeal Carcinoma

Timeline

• Start date: 2022-09-01
• Primary completion: 2022-12-31
• Completion: 2023-12-31
• First posted: 2022-04-15
• Last updated: 2024-07-17

Locations

1 site across 1 country: China